Biotech Clinical Development

Cisema provides tailored clinical development and regulatory services for companies advancing next-generation therapies including Cell and Gene Therapies, CAR-T, monoclonal antibodies, peptides, and RNA-based platforms. With over 20 years of experience across China and the Asia Pacific region, we support biotech innovators through clinical strategy, regulatory planning, and post-market surveillance.

Our bilingual teams across Asia align development plans with regional regulatory frameworks to help you manage risk, secure approvals, and ensure long-term compliance. Whether you are an early-stage biotech or scaling for commercialization, Cisema supports your journey with clarity, precision and cross-border insights.

Biotech clinical development
Expert guidance for the biotech industry

Biotech Clinical Development Services

Strategic Clinical Development Planning

We design development strategies that are tailored to the scientific and regulatory demands of advanced biotech therapies, while aligning with the timelines and milestones critical to fundraising, licensing, and market entry across APAC.

Indication definition and competitive landscape assessment
Preclinical-to-clinical transition strategy for novel modalities
Biomarker integration for patient targeting and pharmacodynamic endpoints
Risk-based planning and early regulatory interaction strategy
Statistical considerations including power analysis to support protocol planning
Pediatric study requirements and mitigation planning.

Regulatory GAP Analysis & Fast-Track Access

Innovative biotech products face evolving and market-specific regulatory expectations. Cisema provides strategic insight to ensure your documentation meets APAC authority standards and supports global expansion.

Review of existing clinical data and technical documentation
Gap identification against regulatory requirements in China and APAC
Recommendations for bridging data, additional studies, or real-world evidence inclusion
Support for Breakthrough Therapy Designation, Priority Review, and Conditional Approval pathways
Early engagement planning for authority interactions and submission readiness.

Submission Preparation & Authority Engagement

Cisema serves as your in-region regulatory representative to coordinate submissions and facilitate interactions with health authorities across APAC.

Submission-ready documentation including IND/CTAs
Preparation of Common Technical Document (CTD) modules
Coordination of health authority and ethics committee Q&A
Regulatory communications
Justification reports, risk management files, and safety narratives.

Post-Market Clinical Support & Real-World Data

We support post-approval evidence generation to maintain compliance and demonstrate long-term product value.

Real world evidence (RWE) study planning and design
Post-market surveillance strategy under China’s MAH system and APAC requirements
PMS documentation, PSUR generation, and signal detection guidance
Support for label extension and stakeholder engagement strategies.

Expertise in Advanced Biotech Modalities

Our services support the clinical development of cutting-edge therapies:

Cell and Gene Therapy, including regenerative medicine and genome editing
CAR-T and cell-based immunotherapies
Antibodies and ADCs, including monoclonal antibodies and fusion proteins
Peptides and proteins, for targeted and sustained therapeutic effects
Biotech platforms involving RNA, microbiome, and companion diagnostics.

Request a Proposal from Our Biotech Team

Let Cisema help turn your plans into reality.

Request Proposal

Why Work with Cisema?

Local expertise with global reach

Our bilingual teams bridge international quality standards with local regulations

Proven track record

Over 20 years supporting market approvals and compliance in China and Asia Pacific

End-to-end solutions

From system setup to post-market surveillance, we ensure quality management and regulatory compliance throughout the product lifecycle

Industry breadth

Cross-sector expertise in life sciences, food, veterinary, consumer and industrial goods

Role of a China Agent

Explore Related Services

Health Economics & Market Access

Accelerate access across China and Asia Pacific with confidence. Our market access consulting experts help life sciences companies optimize patient access, navigate pricing and reimbursement challenges, and enable commercial success through real world evidence, health economics, and tailored access strategies.

Regulatory Affairs

Navigate regulatory complexity across China and Asia Pacific with confidence. Our regulatory affairs consulting experts support biotech companies with strategic planning, compliant submissions, and local representation to accelerate approvals and ensure market readiness.

Pharmacovigilance

Ensure drug safety and regulatory compliance across China and Asia Pacific with confidence. Our pharmacovigilance consulting experts support life sciences companies in managing risks, meeting evolving safety requirements, and maintaining market authorization through end-to-end PV solutions tailored to local regulations.

Quality Management & Compliance

Ensure regulatory excellence across China and Asia Pacific with confidence. Our quality management and compliance experts help life sciences companies strengthen GxP systems, streamline audits, and maintain inspection readiness to safeguard market access and operational performance.

How We’ve Helped Clients with Our Expert Guidance

Read about how we work with clients to find solutions, bringing together deep industry knowledge with leading talent.

View More
April 18, 2026

China Manufacture License Renewal for Level A2 Pressure Vessels

How Cisema Supported Inox Torres Group, S.L. in Successfully Renewing its China Manufacture License (SELO) for Level A2 Pressure Vessels

The China Manufacture License (CML), also known as the SELO license, is a mandatory requirement for manufacturers of pressure equipment intended for the Chinese market. Inox Torres Group, S.L.’s manufacturing site produces high-pressure vessels falling under the Level A2 scope. This license ensures compliance with China’s stringent quality and safety regulations for special equipment.

The Challenge: Managing SELO Complexity for High-Risk Equipment

Renewing a SELO license for Level A2 pressure vessels required careful coordination across regulatory, technical, and cultural dimensions.

  • Navigating Regulatory Complexity
    Navigating the complex and evolving SELO regulatory framework, particularly for high-risk products under Level A2, required meticulous planning and real-time compliance updates.
  • Ensuring Audit Readiness
    Inox Torres Group, S.L. needed to ensure all documentation and procedures were fully up to date and to select an appropriate demo product that met inspection requirements.
  • Managing Inspector Expectations
    Success depended on understanding the unspoken cultural and procedural expectations of SELO inspectors, including hosting and on-site hospitality.

Our Solution: Full-Spectrum SELO Audit Support

Recognizing the high stakes of SELO license renewal, Inox Torres Group, S.L. engaged Cisema for comprehensive regulatory and strategic support.

  • Reviewed the Quality Management System
    Cisema led the review and upgrade of the customer’s quality management system in line with the latest Chinese requirements, including a comprehensive gap analysis and revision of key documentation.
  • Audit Simulation & Preparation
    A preparatory remote audit simulation was conducted, walking through every step of the audit to ensure full readiness ahead of the on-site inspection.
  • Delivered On-Site Bilingual & Regulatory Support
    During the on-site audit, Cisema provided continuous bilingual support, interpreting inspector questions in real time and translating regulatory nuances for the customer.
  • Provided Culturally Appropriate Inspector Hosting
    Cisema arranged culturally appropriate corporate hospitality, helping establish a respectful and positive tone for the inspection. The team remained onsite throughout all audit days, including the weekend, to ensure no detail was overlooked.

The Outcome: Successful Renewal Without Disruption

Through hands-on execution and close coordination, the SELO renewal process was completed smoothly and efficiently.

  • Secured CML Renewal with Full A2 Status
    Inox Torres Group, S.L. successfully renewed its China Manufacture License for pressure vessels, maintaining its Level A2 classification.
  • Executed the Project Efficiently
    Full regulatory preparation and audit execution were completed within six months.
  • Achieved Seamless Inspector Coordination
    SELO inspectors were hosted and coordinated smoothly, with culturally aligned engagement throughout the audit.
  • Secured Regulatory Continuity  
    The renewal avoided operational disruptions and ensured compliance with updated SELO requirements.

Expertise and Efficiency: Acting as an Extension of the Client Team

Cisema’s experienced consultants acted as an extension of Inox Torres Group, S.L.’s regulatory and quality teams, providing both regulatory expertise and strategic foresight. Inspector concerns were anticipated and addressed proactively, transforming a potentially stressful process into a streamlined, well-orchestrated engagement with Chinese authorities.

Hands-on mentoring throughout the project helped the customer gain confidence and clarity in managing future SELO audits.

Why Choose Cisema

  • Strategic Regulatory Expertise: Deep understanding of Chinese bureaucracy, evolving SELO requirements, and inspector expectations.
  • Mentorship & Training: Step-by-step guidance that supported the customer’s quality team throughout the process.
  • Corporate Hospitality Excellence: Culturally aligned hosting that supports successful audit outcomes in China.
  • Audit Readiness & Precision: Gap analysis, audit simulation, and documentation refinement to pass SELO reviews efficiently.
  • End-To-End Support: Full management of the audit process, from document revision to on-site interpretation.

Further Information

Explore Cisema’s China Special Equipment (SELO) Certification services.

Learn More
China Manufacture License Renewal for Level A2 Pressure Vessels
Previous
Previous

Latest Insights

View More

Malaysia Drug–Medical Device Combination Products: A Guide to Classification & Regulatory Pathways

Learn how Malaysia classifies drug–medical device combination products and how the PMOA determines pathways and compliance responsibilities.

April 16, 2026
Malaysia Drug–Medical Device Combination Products: A Guide to Classification & Regulatory Pathways
Laboratory professional in protective eyewear, hair cover, sterile gown, and blue nitrile gloves examining a filled syringe in a clean laboratory environment.

Entering China’s Intraocular Lens (IOL) Market: NMPA Registration Requirements for Foreign Manufacturers

Understand the pathway for intraocular lens (IOL) registration in China, including NMPA requirements and key compliance steps.

April 15, 2026
Entering China’s Intraocular Lens (IOL) Market: NMPA Registration Requirements for Foreign Manufacturers
A close-up of an eye with a transparent intraocular lens held by surgical tweezers positioned in front of the pupil, illustrating ophthalmic medical device use. The visual supports themes of regulatory compliance, product registration, and market access

China Hyaluronic Acid Registration: A Complete Guide

A complete guide to China hyaluronic acid registration, covering classification, NMPA requirements, and compliance steps for manufacturers.

April 16, 2026
China Hyaluronic Acid Registration: A Complete Guide
China Hyaluronic Acid Registration: A Complete Guide

Indonesia's Halal Requirements for Medical Devices: What Manufacturers and Importers Need to Know

Learn which products are covered by Indonesia's halal framework, the labeling and manufacturing obligations, and phased compliance timelines.

April 15, 2026
Indonesia's Halal Requirements for Medical Devices: What Manufacturers and Importers Need to Know
Indonesia's Halal Requirements for Medical Devices: What Manufacturers and Importers Need to Know

Medical Device Registration in Indonesia: A Practical Guide for Foreign Manufacturers

Learn how to register medical devices in Indonesia, including Authorized Representative rules, classification, dossiers, timelines, and fees.

April 15, 2026
Medical Device Registration in Indonesia: A Practical Guide for Foreign Manufacturers
Medical Device Registration in Indonesia: A Practical Guide for Foreign Manufacturers

Medical Devices in China: A Regulatory Glossary for NMPA Compliance

Practical China medical device glossary explaining NMPA terms, with clear comparisons to US FDA and EU MDR terminology.

April 15, 2026
Medical Devices in China: A Regulatory Glossary for NMPA Compliance
Medical Devices in China: A Regulatory Glossary for NMPA Compliance
Previous
Previous

Contact Our Biotech Clinical Development Consultants

Let’s discuss how we can support your cell and gene therapy, CAR-T, antibody, or peptide product.

Request Proposal